An oft-repeated message is that primary aldosteronism is not rare; it is quite common. An equally urgent message is that ...

In patients with frequent severe hypoglycaemic events, allogeneic pancreatic islet transplantation results in better glycaemic control than insulin therapy alone, enhances quality of life, and reduces ...

The US President's Emergency Plan for AIDS Relief (PEPFAR) faces a pivotal moment, confronting one of its most challenging periods since its launch in 2003. The new policy priorities of the ...

We write to alert Lancet readers that, as of Feb 1, 2025, all US research and websites published by federal scientists and agencies are now subject to new edicts issued by the Trump administration1,2 ...

The increasing frequency and severity of environmental disasters necessitate robust health-care system adaptation strategies. Recent wildfire events in and around Los Angeles County, CA, USA, are ...

Angola's Ministry of Health has released alarming statistics regarding the ongoing cholera outbreak,1,2 highlighting a severe public health crisis that warrants immediate international attention. By ...

We are facing a new threat to global health. The COVID-19 pandemic made it clear to health-care providers, public health practitioners, policy makers, and communities that pathogens do not respect ...

In this issue of The Lancet Diabetes & Endocrinology, Michelle M Chen and colleagues1 report their findings on trends in the incidence of thyroid cancer in the USA from 1975 to 2019. The authors show ...

All physicians are faced with the challenge of how to help patients with no approved therapies for their diseases. What are ...

The announcement by US President Donald Trump that the USA will withdraw from WHO1 will leave both a large financial gap and ...

Afghanistan's de facto authorities have made the alarming decision to ban women from studying nursing and midwifery.1 This policy, along with the broader ban on girls completing education beyond grade ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...